European Cancer Deals Increasingly Focus on Natural Killer Cells
Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene,…
Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene,…
Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American…
The French big pharma Sanofi has offered €308M to acquire the Dutch firm Kiadis Pharma…
The Dutch biotech Kiadis Pharma has licensed an off-the-shelf cell therapy program to the pharma…
The Dutch company Kiadis Pharma has discontinued the development of a cell therapy in blood…
The Dutch Kiadis Pharma has raised €27.6M in a private placement to fund the clinical…
Although biotech may seem like an industry that has only just gotten started, it was…
Kiadis Pharma starts Phase III trials with ATIR101, a therapy that could make half-matched donors…
The FDA has backed Kiadis Pharma's lead blood cancer product by granting it the Regenerative Medicine…
Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing…
Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune…
Kiadis Pharma has received green light from the EMA to start a Phase II trial of…